John L. Higgins's most recent trade in OmniAb Inc was a trade of 40,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| OmniAb Inc | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 2,851,887 | - | - | Common Stock | |
| OmniAb Inc | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 33,172 | - | - | Restricted Stock Units | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2025 | 20,000 | 13,172 | - | - | Restricted Stock Units | |
| OmniAb Inc | John L. Higgins | Director | Purchase of securities on an exchange or from another person at price $ 1.44 per share. | 12 May 2025 | 65,000 | 2,831,887 | - | 1.4 | 93,600 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 12,000 | 5,040 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.84 per share. | 01 May 2025 | 12,000 | 60,196 (0%) | 0% | 21.8 | 262,080 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 21 Mar 2025 | 4,000 | 2,766,887 | - | 2.3 | 9,120 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Purchase of securities on an exchange or from another person at price $ 2.35 per share. | 20 Mar 2025 | 125,750 | 2,762,887 | - | 2.4 | 295,513 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 13,172 | 2,637,137 | - | - | Common Stock | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 13,172 | 33,172 | - | - | Restricted Stock Units | |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 3,511 | 3,511 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2024 | 1,462 | 48,196 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 12 Sep 2024 | 6,000 | 48,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2024 | 6,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.20 per share. | 12 Sep 2024 | 1,874 | 46,734 (0%) | 0% | 73.2 | 137,177 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 08 Jul 2024 | 6,000 | 42,608 (0%) | 0% | 23.0 | 137,700 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2024 | 6,000 | 6,000 | - | - | Stock Options (Right to Buy) | |
| OmniAb Inc | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| OmniAb Inc | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 46,344 | - | - | Restricted Stock Units | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 26,344 | - | - | Restricted Stock Units | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 20,000 | 2,623,965 | - | - | Common Stock | |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 4,000 | 12,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 83.84 per share. | 14 May 2024 | 4,000 | 36,608 (0%) | 0% | 83.8 | 335,377 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.95 per share. | 14 May 2024 | 4,000 | 40,608 (0%) | 0% | 23.0 | 91,800 | Common Stock |
| OmniAb Inc | John Higgins L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 13,173 | 2,352,625 | - | - | Common Stock | |
| OmniAb Inc | John Higgins L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 13,173 | 46,344 | - | - | Restricted Stock Units | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 23 May 2023 | 9,000 | 2,471,686 | - | 3.7 | 33,120 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 23 May 2023 | 9,000 | 2,462,686 | - | 4.1 | 36,450 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,000 | 1,362 | - | - | Stock Option | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 1,000 | 10,362 | - | - | Stock Option | |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 19 May 2023 | 1,000 | 2,463,686 | - | 3.7 | 3,680 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 4.05 per share. | 19 May 2023 | 1,000 | 2,462,686 | - | 4.1 | 4,050 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.68 per share. | 18 May 2023 | 50,000 | 2,512,686 | - | 3.7 | 184,000 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2023 | 50,000 | 11,362 | - | - | Stock Option | |
| OmniAb Inc | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 3.89 per share. | 18 May 2023 | 50,000 | 2,462,686 | - | 3.9 | 194,500 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 16,000 | 0 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.85 per share. | 28 Apr 2023 | 16,000 | 39,360 (0%) | 0% | 21.9 | 349,600 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.88 per share. | 28 Apr 2023 | 4,377 | 34,983 (0%) | 0% | 79.9 | 349,635 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.29 per share. | 28 Dec 2022 | 5,289 | 417,695 (2%) | 0% | 66.3 | 350,608 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 92,932 | 92,932 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 61.87 per share. | 16 Dec 2022 | 10,000 | 422,984 (2%) | 0% | 61.9 | 618,657 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.78 per share. | 12 Dec 2022 | 20,000 | 436,928 (2%) | 0% | 12.8 | 255,600 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 20,000 | 20,335 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director | Sale or transfer of securities back to the company at price $ 64.80 per share. | 12 Dec 2022 | 3,944 | 432,984 (2%) | 0% | 64.8 | 255,571 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.90 per share. | 30 Nov 2022 | 9,803 | 416,928 (2%) | 0% | 72.9 | 714,639 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.78 per share. | 17 Nov 2022 | 10,000 | 426,731 (2%) | 0% | 12.8 | 127,800 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2022 | 10,000 | 40,335 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 78.32 per share. | 17 Nov 2022 | 10,000 | 416,731 (2%) | 0% | 78.3 | 783,173 | Common Stock |
| OmniAb Inc | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 2,427,861 | 2,603,965 | - | - | Common Stock | |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 865 | 865 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Oct 2022 | 338 | 5,840 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 88.06 per share. | 16 Sep 2022 | 1,000 | 366,180 (2%) | 0% | 88.1 | 88,060 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 10 Aug 2022 | 3,400 | 8,006 (0%) | 0% | 66.9 | 227,460 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2022 | 3,400 | 0 | - | - | Stock Option (right to buy) | |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.15 per share. | 10 Aug 2022 | 992 | 6,014 (0%) | 0% | 380.2 | 377,112 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 373.99 per share. | 10 Aug 2022 | 900 | 7,106 (0%) | 0% | 374.0 | 336,593 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 385.47 per share. | 10 Aug 2022 | 504 | 5,510 (0%) | 0% | 385.5 | 194,277 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 374.90 per share. | 10 Aug 2022 | 100 | 7,006 (0%) | 0% | 374.9 | 37,490 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 380.75 per share. | 10 Aug 2022 | 8 | 5,502 (0%) | 0% | 380.8 | 3,046 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Other type of transaction at price $ 75.84 per share. | 30 Jun 2022 | 164 | 369,180 (2%) | 0% | 75.8 | 12,437 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 20,423 | 369,016 (2%) | 0% | 0 | Common Stock | |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 364.31 per share. | 07 Jun 2022 | 1,000 | 4,606 (0%) | 0% | 364.3 | 364,310 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 1,000 | 5,606 (0%) | 0% | 66.9 | 66,900 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 1,000 | 4,000 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2022 | 600 | 3,400 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne | John L. Higgins | Director | Sale of securities on an exchange or to another person at price $ 366.09 per share. | 07 Jun 2022 | 600 | 4,606 (0%) | 0% | 366.1 | 219,654 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.90 per share. | 07 Jun 2022 | 600 | 5,206 (0%) | 0% | 66.9 | 40,140 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.92 per share. | 09 May 2022 | 8,000 | 348,593 (2%) | 0% | 21.9 | 175,360 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 8,000 | 57,616 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 76,478 | 76,478 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 2,061 | 342,509 (2%) | 0% | 123.7 | 254,904 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,946 | 344,570 (2%) | 0% | 123.7 | 240,681 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.68 per share. | 15 Feb 2022 | 1,916 | 340,593 (2%) | 0% | 123.7 | 236,971 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 13,560 | 358,261 (2%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 9,606 | 344,701 (2%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.68 per share. | 26 Jan 2022 | 6,183 | 349,018 (2%) | 0% | 113.7 | 702,883 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.68 per share. | 26 Jan 2022 | 3,060 | 355,201 (2%) | 0% | 113.7 | 347,861 | Common Stock |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 633 | 633 | - | - | Stock Option (right to buy) | |
| Bio-Techne | John L. Higgins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 194 | 4,606 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Other type of transaction at price $ 85.91 per share. | 30 Jun 2021 | 247 | 338,095 (2%) | 0% | 85.9 | 21,220 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 2,061 | 337,848 (2%) | 0% | 172.5 | 355,440 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 1,947 | 339,909 (2%) | 0% | 172.5 | 335,780 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 172.46 per share. | 15 Feb 2021 | 1,204 | 341,856 (2%) | 0% | 172.5 | 207,642 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 60,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.05 per share. | 05 Feb 2021 | 60,000 | 346,030 (2%) | 0% | 10.1 | 603,000 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 203.40 per share. | 05 Feb 2021 | 54,666 | 286,030 (1%) | 0% | 203.4 | 11,119,239 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 54,666 | 14,334 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.47 per share. | 05 Feb 2021 | 54,666 | 340,696 (2%) | 0% | 14.5 | 791,017 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 203.03 per share. | 05 Feb 2021 | 2,970 | 343,060 (2%) | 0% | 203.0 | 602,999 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 25,113 | 25,113 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 12,608 | 286,030 (1%) | 0% | 0 | Common Stock | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 50,000 | 109,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.47 per share. | 25 Jan 2021 | 50,000 | 285,310 (1%) | 0% | 14.5 | 723,500 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 159.00 per share. | 25 Jan 2021 | 50,000 | 235,310 (1%) | 0% | 159 | 7,950,000 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 40,000 | 69,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 182.00 per share. | 25 Jan 2021 | 40,000 | 243,422 (1%) | 0% | 182 | 7,280,000 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.47 per share. | 25 Jan 2021 | 40,000 | 283,422 (1%) | 0% | 14.5 | 578,800 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.92 per share. | 25 Jan 2021 | 30,000 | 273,422 (1%) | 0% | 21.9 | 657,600 | Common Stock |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2021 | 30,000 | 65,616 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharmaceuticals, In... | John L. Higgins | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 9,607 | 248,018 (1%) | 0% | 0 | Common Stock |